Cargando…

Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes

PURPOSE: This study sought to characterize transcriptional phenotypes of COPD through unsupervised clustering of sputum gene expression profiles, and further investigate mechanisms underlying the characteristics of these clusters. PATIENTS AND METHODS: Induced sputum samples were collected from pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Negewo, Netsanet A, Gibson, Peter G, Simpson, Jodie L, McDonald, Vanessa M, Baines, Katherine J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024507/
https://www.ncbi.nlm.nih.gov/pubmed/36942279
http://dx.doi.org/10.2147/COPD.S388297
_version_ 1784909121463517184
author Negewo, Netsanet A
Gibson, Peter G
Simpson, Jodie L
McDonald, Vanessa M
Baines, Katherine J
author_facet Negewo, Netsanet A
Gibson, Peter G
Simpson, Jodie L
McDonald, Vanessa M
Baines, Katherine J
author_sort Negewo, Netsanet A
collection PubMed
description PURPOSE: This study sought to characterize transcriptional phenotypes of COPD through unsupervised clustering of sputum gene expression profiles, and further investigate mechanisms underlying the characteristics of these clusters. PATIENTS AND METHODS: Induced sputum samples were collected from patients with stable COPD (n = 72) and healthy controls (n = 15). Induced sputum was collected for inflammatory cell counts, and RNA extracted. Transcriptional profiles were generated (Illumina Humanref-8 V2) and analyzed by GeneSpring GX14.9.1. Unsupervised hierarchical clustering and differential gene expression analysis were performed, and gene alterations validated in the ECLIPSE dataset (GSE22148). RESULTS: We identified 2 main clusters (Cluster 1 [n = 35] and Cluster 2 [n = 37]), which further divided into 4 sub-clusters (Sub-clusters 1.1 [n = 14], 1.2 [n = 21], 2.1 [n = 20] and 2.2 [n = 17]). Compared with Cluster 1, Cluster 2 was associated with significantly lower lung function (p = 0.014), more severe disease (p = 0.009) and breathlessness (p = 0.035), and increased sputum neutrophils (p = 0.031). Sub-cluster 1.1 had significantly higher proportion of people with comorbid cardiovascular disease compared to the other 3 sub-clusters (92.5% vs 57.1%, 50% and 52.9%, p < 0.013). Through supervised analysis we determined that degree of airflow limitation (GOLD stage) was the predominant factor driving gene expression differences in our transcriptional clusters. There were 452 genes (adjusted p < 0.05 and ≥2 fold) altered in GOLD stage 3 and 4 versus 1 and 2, of which 281 (62%) were also found to be significantly expressed between these GOLD stages in the ECLIPSE data set (GSE22148). Differentially expressed genes were largely downregulated in GOLD stages 3 and 4 and connected in 5 networks relating to lipoprotein and cholesterol metabolism; metabolic processes in oxidation/reduction and mitochondrial function; antigen processing and presentation; regulation of complement activation and innate immune responses; and immune and metabolic processes. CONCLUSION: Severity of lung function drives 2 distinct transcriptional phenotypes of COPD and relates to immune and metabolic processes.
format Online
Article
Text
id pubmed-10024507
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100245072023-03-19 Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes Negewo, Netsanet A Gibson, Peter G Simpson, Jodie L McDonald, Vanessa M Baines, Katherine J Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: This study sought to characterize transcriptional phenotypes of COPD through unsupervised clustering of sputum gene expression profiles, and further investigate mechanisms underlying the characteristics of these clusters. PATIENTS AND METHODS: Induced sputum samples were collected from patients with stable COPD (n = 72) and healthy controls (n = 15). Induced sputum was collected for inflammatory cell counts, and RNA extracted. Transcriptional profiles were generated (Illumina Humanref-8 V2) and analyzed by GeneSpring GX14.9.1. Unsupervised hierarchical clustering and differential gene expression analysis were performed, and gene alterations validated in the ECLIPSE dataset (GSE22148). RESULTS: We identified 2 main clusters (Cluster 1 [n = 35] and Cluster 2 [n = 37]), which further divided into 4 sub-clusters (Sub-clusters 1.1 [n = 14], 1.2 [n = 21], 2.1 [n = 20] and 2.2 [n = 17]). Compared with Cluster 1, Cluster 2 was associated with significantly lower lung function (p = 0.014), more severe disease (p = 0.009) and breathlessness (p = 0.035), and increased sputum neutrophils (p = 0.031). Sub-cluster 1.1 had significantly higher proportion of people with comorbid cardiovascular disease compared to the other 3 sub-clusters (92.5% vs 57.1%, 50% and 52.9%, p < 0.013). Through supervised analysis we determined that degree of airflow limitation (GOLD stage) was the predominant factor driving gene expression differences in our transcriptional clusters. There were 452 genes (adjusted p < 0.05 and ≥2 fold) altered in GOLD stage 3 and 4 versus 1 and 2, of which 281 (62%) were also found to be significantly expressed between these GOLD stages in the ECLIPSE data set (GSE22148). Differentially expressed genes were largely downregulated in GOLD stages 3 and 4 and connected in 5 networks relating to lipoprotein and cholesterol metabolism; metabolic processes in oxidation/reduction and mitochondrial function; antigen processing and presentation; regulation of complement activation and innate immune responses; and immune and metabolic processes. CONCLUSION: Severity of lung function drives 2 distinct transcriptional phenotypes of COPD and relates to immune and metabolic processes. Dove 2023-03-14 /pmc/articles/PMC10024507/ /pubmed/36942279 http://dx.doi.org/10.2147/COPD.S388297 Text en © 2023 Negewo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Negewo, Netsanet A
Gibson, Peter G
Simpson, Jodie L
McDonald, Vanessa M
Baines, Katherine J
Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes
title Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes
title_full Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes
title_fullStr Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes
title_full_unstemmed Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes
title_short Severity of Lung Function Impairment Drives Transcriptional Phenotypes of COPD and Relates to Immune and Metabolic Processes
title_sort severity of lung function impairment drives transcriptional phenotypes of copd and relates to immune and metabolic processes
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024507/
https://www.ncbi.nlm.nih.gov/pubmed/36942279
http://dx.doi.org/10.2147/COPD.S388297
work_keys_str_mv AT negewonetsaneta severityoflungfunctionimpairmentdrivestranscriptionalphenotypesofcopdandrelatestoimmuneandmetabolicprocesses
AT gibsonpeterg severityoflungfunctionimpairmentdrivestranscriptionalphenotypesofcopdandrelatestoimmuneandmetabolicprocesses
AT simpsonjodiel severityoflungfunctionimpairmentdrivestranscriptionalphenotypesofcopdandrelatestoimmuneandmetabolicprocesses
AT mcdonaldvanessam severityoflungfunctionimpairmentdrivestranscriptionalphenotypesofcopdandrelatestoimmuneandmetabolicprocesses
AT baineskatherinej severityoflungfunctionimpairmentdrivestranscriptionalphenotypesofcopdandrelatestoimmuneandmetabolicprocesses